Bristol Myers Squibb Raises 2026 Revenue Forecast as Newer Drugs Drive Q3 Growth
The Bristol Myers Squibb Q3 2026 results lift revenue guidance as newer drugs grow 12%. EPS fell on a $1.6 billion charge.
Maharashtra FDA Cancels Cipla Pune Warehouse Drug Licences
Maharashtra FDA cancelled the drug sale and distribution licences of Cipla Pune Wadki warehouse on 1 October over alleged lapses. Cipla calls it disappointing.
FDA Extends Review of Novo Denecimig Over Facility Issues
FDA extended its denecimig review as manufacturing-site remediation continues. No efficacy or safety issues were cited; Novo now expects a US launch in H1 2027.
Pennsylvania Measles Outbreak Nears 1,000 With 977 Cases
Pennsylvania measles outbreak reached 977 confirmed cases in 39 counties as of 2 October, with 195 hospitalised and five deaths; MMR doses have surged.
Bayer Ohio Plant: $2.2 Billion Pharma Site in New Albany
Bayer will invest $2.2 billion in a New Albany, Ohio pharmaceutical campus with about 600 permanent jobs; the first module is due by 2031.
Datroway Ivonescimab Phase III Planned in First-Line TNBC
Datroway ivonescimab trials will start with a Phase III in first-line triple-negative breast cancer in a new AstraZeneca, Daiichi Sankyo and Summit pact.
Novartis Abogen Deal: $7.8 Billion mRNA Autoimmune License
Novartis Abogen deal: Abogen gets $575 million upfront and up to $7.2 billion in milestones for ABO2203, an mRNA T-cell engager for autoimmune disease.
PRIP Scheme: India Backs 41 Pharma, MedTech R&D Projects
PRIP scheme: India approved about ₹1,600 crore for 41 pharma and MedTech R&D projects, expected to draw ₹3,020 crore more in private investment.
FHD-909 Discontinued: Foghorn and Lilly End SMARCA2 Program
FHD-909 discontinued: Foghorn and Lilly will not advance the SMARCA2 inhibitor after Phase 1 data, and Foghorn is cutting about 40% of its workforce.
Survodutide Weight Loss: Up to 13.1% in Phase III Trial
Survodutide weight loss reached up to 13.1% versus 3.1% on placebo at 76 weeks in the Phase III SYNCHRONIZE-2 trial in people with type 2 diabetes.
Trevogrumab Preserves Muscle During Semaglutide Weight Loss
Trevogrumab added to semaglutide cut lean muscle loss in Regeneron's nearly 1,000-patient trial, preserving over 70% of thigh muscle at 52 weeks.